LGALS3 and asthma: However, the most interesting finding was the recent observation that Gal-3 may be considered as a new biomarker predictive of long-term responsiveness of pulmonary function in patients with severe asthma treated with the monoclonal antibody, anti-immunoglobulin E (IgE), named omalizumab [77].